# Nuclide record opp-trop2-imaging-heterogeneity (opportunity). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/opportunities/opp-trop2-imaging-heterogeneity/>
  a schema:CreativeWork ;
  nuclide:kind "opportunity" ;
  schema:identifier "opp-trop2-imaging-heterogeneity" ;
  schema:name "TROP2 imaging where no tissue test is required"@en ;
  schema:alternateName "TROP2 PET"@en, "Trop-2 imaging"@en ;
  schema:description "Two approved breast cancer drugs work through a protein called TROP2, and neither requires any test for it before use. Tumours vary a lot in how much they carry, and a quarter of patients lose it over time, so nobody currently knows who is being treated for a target that is no longer there."@en ;
  schema:url <https://nuclide.cc/opportunities/opp-trop2-imaging-heterogeneity/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://www.thno.org/v16p8117.htm>, <https://pubmed.ncbi.nlm.nih.gov/34116144/>, <https://biomarker.onclive.com/breast-cancer/triple-negative-tnbc/biomarkers/trop2>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC13379550/>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast> ;
  nuclide:tag "target crossover", "breast", "heterogeneity", "nanobody" ;
  nuclide:related <https://nuclide.cc/isotopes/ga-68/> ;
  nuclide:indications <https://nuclide.cc/indications/breast-triple-negative/> ;
  nuclide:technologies <https://nuclide.cc/technologies/trop2-pet/>, <https://nuclide.cc/technologies/immuno-pet/>, <https://nuclide.cc/technologies/pet-ct/> ;
  nuclide:targets <https://nuclide.cc/targets/trop2/> .